Navigation Links
Genzyme Reports Strong Second-Quarter Growth
Date:7/23/2008

Delivers Solid Financial Performance While Building for the Future

CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported strong sales and profit growth in the second quarter, along with significant progress in its commercial and clinical programs.

Revenue increased 25 percent to approximately $1.171 billion from $933.4 million in last year's second quarter. The increase was driven by growth across all areas of the business.

GAAP net income was $69.6 million, or $0.25 per diluted share, compared with $83.8 million, or $0.31 per diluted share, in the second quarter a year ago. GAAP net income reflects the fee for the license to mipomersen, a highly promising cholesterol-lowering drug in late-stage development.

Non-GAAP net income increased to $268.5 million from $238.7 million in last year's second quarter. Non-GAAP earnings increased to $0.98 per diluted share from $0.88.

Genzyme continues to reinvest cash from operations to build a foundation for long-term growth. In the second quarter, the company generated approximately $329 million in cash from net income prior to one-time events and proceeds from the issuance of common stock. The company made a $175 million payment to Isis Pharmaceuticals to secure the rights to mipomersen, significantly strengthening its late-stage pipeline. Genzyme also invested approximately $130 million in capital projects, predominantly focused on expanding manufacturing capacity to meet current and anticipated product demand. To reduce the dilutive effect of equity compensation, the company used a portion of its cash to repurchase 1 million shares under its three-year stock buyback program.

"It was a strong and highly prod
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com announces ... in its catalogue: Global Chelating Agents ... About Chelating Agent A chelating agent ... bonds with metal ions, thereby forming a metal-ion ... metal-ions have on chemical processes, formulations, and the ...
(Date:8/27/2014)... YORK , Aug. 27, 2014 Guggenheim ... Guggenheim Partners, today announced the hiring of veteran equity ... senior equity analyst. Mr. Butler will focus on the ... our team a wealth of experience and a broad ... Ferrarie , Senior Managing Director and Head of Equities ...
(Date:8/27/2014)...  ARCH Venture Partners, one of the largest ... of seed and early-stage advanced technology companies, today ... more than $400 million in subscriptions. ARCH Venture ... by more than $150 million. "The ... potential of our approach to finding and funding ...
(Date:8/27/2014)... White City, OR (PRWEB) August 27, 2014 ... Supply Report, “Consolidation continues to reshape the look and ... in nutrition. Consumer demand for higher-quality ingredients will push ... the North American market have experienced strong market growth ... and ethical attributes in their food and cosmetics to ...
Breaking Biology Technology:Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3
... Distributor in Greece, to Purchase an Aggregate ... of Over $200,000 of Resurgex(R) in 2008, ... wholly owned subsidiary of Millennium,Biotechnologies Group, Inc. (OTC Bulletin Board: ... order for the international,distribution of the Resurgex(R) line in Greece. ...
... CAMBRIDGE, Mass., April 1, 2008 Abt ... Abt Bio-Pharma Solutions, Inc., a,wholly owned subsidiary of ... custom strategic, research and communication solutions for the,pharmaceutical, ... approach that blends decades of experience with wide,ranging ...
... MONTREAL, April 1 /PRNewswire-FirstCall/ - AEterna,Zentaris Inc. ... global biopharmaceutical company,focused on endocrine therapy and ... leading Canadian specialty pharmaceutical company, announced today,that, ... transactions under their,previously announced purchase and sale ...
Cached Biology Technology:Millennium Announces $200,000 Purchase Order From Greek Distributor 2Millennium Announces $200,000 Purchase Order From Greek Distributor 3Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc. 2AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights 2AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights 3
(Date:8/27/2014)... to Europe based upon a proxy for impact have ... ,big data, approach to scientific research. , The researchers ... ranked the top 100 pathogens affecting humans and the ... they believe, will help governments across the continent plan ... including as a result of climate change, and for ...
(Date:8/27/2014)... . , Charcot-Marie-Tooth ... affecting the peripheral nervous system. Researchers from the Department ... Medicine and University Medical Centre Gttingen have discovered that ... with the disease. These cells enwrap the nerve fibres ... the rapid transfer of electrical impulses. If Schwann cells ...
(Date:8/27/2014)... York, NY (June, 2014) Outstanding basic research, ... and a dedication to patient care have earned ... Columbia University Medical Center (CUMC) and NewYork-Presbyterian Hospital ... from the National Cancer Institute (NCI). The grant ... two NCI-designated Comprehensive Cancer Centers in New York ...
Breaking Biology News(10 mins):Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Potential therapy for incurable Charcot-Marie-Tooth disease 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4
... has named its awardee for this year,s Alan ... Brown University. Dunn,s work involves genome analyses ... He investigates the origins of biological complexity ... research holds clues about how complex multicellular organisms, ...
... This release is available in French . ... without exposing the healthy surrounding tissue to the medication,s toxic ... medical reality, thanks to the work of Professor Sylvain Martel, ... Known for being the world,s first researcher to have guided ...
... most controversial aspects in the sustainable management of golf courses. ... the practices relating to reclaimed water at one of the ... on the course receive 83% more water than they need. ... be justified from any perspective", Mara del Pino Palacios Daz, ...
Cached Biology News:Casey Dunn to receive NSF Waterman Award 2Casey Dunn to receive NSF Waterman Award 3World first -- Localized delivery of an anti-cancer drug by remote-controlled microcarriers 2Golf courses that reuse water irrigate too much 2Golf courses that reuse water irrigate too much 3
Yersinia pestis...
Rabbit polyclonal to Olfactory Receptor LS189744 ( Abpromise for all tested applications)....
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Mouse monoclonal [11C9] to Zeralenone ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to BSA: Zeralenone...
Biology Products: